Larson Financial Group’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-4,034
| Closed | -$86.9K | – | 3641 |
|
|
2025
Q4 | $86.9K | Buy |
4,034
+33
| +0.8% | +$641 | ﹤0.01% | 979 |
|
|
2025
Q3 | $61.1K | Buy |
4,001
+1
| +0% | +$13 | ﹤0.01% | 1081 |
|
|
2025
Q2 | $35.4K | Hold |
4,000
| – | – | ﹤0.01% | 1216 |
|
|
2025
Q1 | $31.3K | Hold |
4,000
| – | – | ﹤0.01% | 1201 |
|
|
2024
Q4 | $42K | Hold |
4,000
| – | – | ﹤0.01% | 956 |
|
|
2024
Q3 | $52.5K | Hold |
4,000
| – | – | ﹤0.01% | 895 |
|
|
2024
Q2 | $56.2K | Hold |
4,000
| – | – | ﹤0.01% | 780 |
|
|
2024
Q1 | $67.6K | Hold |
4,000
| – | – | 0.01% | 623 |
|
|
2023
Q4 | $56.5K | Hold |
4,000
| – | – | ﹤0.01% | 620 |
|
|
2023
Q3 | $41.2K | Hold |
4,000
| – | – | ﹤0.01% | 664 |
|
|
2023
Q2 | $65.9K | Hold |
4,000
| – | – | 0.01% | 496 |
|
|
2023
Q1 | $36.6K | Hold |
4,000
| – | – | ﹤0.01% | 611 |
|
|
2022
Q4 | $28.6K | Hold |
4,000
| – | – | ﹤0.01% | 623 |
|
|
2022
Q3 | $20K | Hold |
4,000
| – | – | ﹤0.01% | 629 |
|
|
2022
Q2 | $10K | Hold |
4,000
| – | – | ﹤0.01% | 714 |
|
|
2022
Q1 | $27K | Hold |
4,000
| – | – | ﹤0.01% | 475 |
|
|
2021
Q4 | $32K | Hold |
4,000
| – | – | 0.01% | 459 |
|
|
2021
Q3 | $39K | Hold |
4,000
| – | – | 0.01% | 340 |
|
|
2021
Q2 | $27K | Hold |
4,000
| – | – | 0.01% | 384 |
|
|
2021
Q1 | $36K | Hold |
4,000
| – | – | 0.01% | 304 |
|
|
2020
Q4 | $27K | Hold |
4,000
| – | – | 0.01% | 307 |
|
|
2020
Q3 | $20K | Hold |
4,000
| – | – | 0.01% | 320 |
|
|
2020
Q2 | $32K | Hold |
4,000
| – | – | 0.02% | 231 |
|
|
2020
Q1 | $32K | Hold |
4,000
| – | – | 0.02% | 183 |
|
|
2019
Q4 | $30K | Hold |
4,000
| – | – | 0.02% | 186 |
|
|
2019
Q3 | $17K | Buy |
+4,000
| New | +$10K | 0.01% | 236 |
|
Other funds holding AVDL
Larson Financial Group's AVDL Position: Q1 2026 in Review
Larson Financial Group sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 4,034 shares — an estimated $86.9K sold.
Larson Financial Group first reported a position in AVDL in Q3 2019 and held it in 26 quarters. The position peaked at $86.9K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Larson Financial Group reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Larson Financial Group sold 4,034 Avadel Pharmaceuticals shares in Q1 2026, an estimated $86.9K.
- Larson Financial Group first reported a position in Avadel Pharmaceuticals in Q3 2019 and held it in 26 quarters.
- Larson Financial Group's Avadel Pharmaceuticals position peaked at $86.9K in Q4 2025.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.